Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 5Thoracic 3Plasma cell 3Gastrointestinal 3Breast 3Tumor-Agnostic 2Head & Neck 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 3Nausea 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Olanzapine × Breast × Clear all
NCT03367572 2025-09-25

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

University of Rochester

Phase 3 Completed
1,363 enrolled 20 charts
Breast

Breast Neoplasms

NCT04669132 2022-02-23

OLNEPA

Instituto Brasileiro de Controle do Cancer

Phase 2 Completed
50 enrolled
Breast

Breast Neoplasms, Nausea

NCT02861859 2020-02-26

Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study

Ottawa Hospital Research Institute

Phase 3 Completed
221 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡